CompletedPhase 4

Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

United States40 participantsStarted 2017-07-20

Plain-language summary

This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient must meet 1987 ACR criteria
✓. Age \> 18 years of age
✓. Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) \>=3.2
✓. Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)
✓. Stable prednisone \<10mg or equivalent
✓. Power Doppler score of \>=10

Exclusion criteria

✕. Prior treatment with Acthar in the past 2mos
✕. Meet one of the above RA flare requirements
✕. Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

What they're measuring

Ultrasound Power Doppler Score

Timeframe: Baseline to 2 Weeks

DAS28

Timeframe: Baseline to 2 Weeks

Trial details

NCT IDNCT02541955

SponsorVeena Ranganath, MD, MS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-06

View on ClinicalTrials.gov More Rheumatoid Arthritis (RA) trials